Gilead completes Pharmasset tender offer
This article was originally published in Scrip
Executive Summary
Gilead Sciences says it has finalised its tender offer for Pharmasset. The firm had announced in late November that it would pay $137 per share in cash, or about $11 billion, for the drug developer in order to gain access to its three clinical-stage hepatitis C virus product candidates and compete more effectively with the newly approved drugs from Vertex and Merck (scripintelligence.com, 21 November 2011).